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The novel coronavirus disease of 2019 (COVID-19) pandemic, as declared by the World 
Health Organization, is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) 
[1,2]. Cardiovascular disease and, in particular, venous thromboembolism (VTE) has emerged as an 
important consideration in the management of hospitalized patients with COVID-19. The diagnosis of 
VTE using standardized objective testing is problematic in these patients, given the risk of infecting 
non-COVID-19 hospitalized patients and hospital personnel, coupled with the usual challenges of 
performing diagnostic testing in critically-ill patients. Early reports suggest a high incidence of VTE 
in hospitalized COVID-19 patients, particularly those with severe illness, that is similar to the high 
VTE rates observed in patients with other viral pneumonias, including severe acute respiratory 
syndrome (SARS) and Middle East respiratory syndrome (MERS-CoV) [3–6] . COVID-19 is 
associated with marked abnormalities in markers of hypercoagulability, including elevated levels of 
D-dimer, fibrinogen, and factor VIII, a shortened activated partial thromboplastin time (aPTT) and an 
elevated sepsis induced coagulopathy (SIC) score [7] . Investigational therapies for the management 
of severely ill COVID-19 patients may carry an increased risk for VTE or have implications for drug-
drug interactions with established agents used for the acute and chronic management of VTE, such as 
the direct oral anticoagulants (DOACs) and Vitamin K antagonists such as warfarin.
Hospitalized COVID-19 patients share similar strong clinical intrinsic and extrinsic risk 
factors for VTE, which include advanced age, obesity, immobility/stroke with paralysis, a history of 
cancer/active cancer, management in an intensive care unit (ICU)/coronary care unit (CCU) setting, a 
prior history of VTE or known thrombophilia, that are present in hospitalized medically ill patients 
[7,8] . However, risk stratification for VTE and the optimal intensity and duration of anticoagulant 
thromboprophylaxis, including post-hospital discharge prophylaxis, remains uncertain in hospitalized 
COVID-19 patients. 
The overall objective of this guidance from the Scientific and Standardization Committee 
(SSC) of the ISTH, developed by a multidisciplinary panel of experts in thrombosis and haemostasis, 
is to provide practical guidance for the management of VTE in hospitalized patients with suspected or 
confirmed COVID-19 infection. Specific objectives are: 1) to provide an approach to the diagnosis of 
VTE; 2) to provide guidance on thromboprophylaxis strategies in ICU and non-ICU settings, 
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Methods
This guidance statement is a collaborative effort of the Perioperative and Critical Care 
Thrombosis and Haemostasis, along with members of the Control of Anticoagulation and 
Disseminated Intravascular Coagulation Subcommittees of the SCC. The guidance provided is 
anchored on a narrative review of pertinent literature, with a search occurring until April 18, 2020, 
coupled with responses to a standardized and independently administered survey of preferred 
practices related to the diagnosis, prevention, and treatment of VTE in COVID-19 patients 
(Appendix) and conducted by the McMaster Centre for Transfusion Medicine using an independent, 
multi-institutional, and multidisciplinary panel of experts in the field of thrombosis and haemostasis.
The survey of experts was done using a single cross-sectional assessment approach with an 
expectation that all (100%) panelists would select a pre-specified management option or to indicate, 
through the “other option” category that alternative management was preferred. This one-time 
approach, rather than a multi-step, iterative approach (e.g., Delphi method), was deemed appropriate 
in the context of the topic (COVID-19 and thrombosis) where requisite evidence, typically used in an 
iterative approach, is not available. Our aim was to identify where consensus existed and, of equal 
importance, to identify where there was a lack of consensus on clinical management. 
The Diagnosis of VTE in Hospitalized COVID-19 Patients
The diagnostic assessment of suspected VTE in hospitalized COVID-19 patients is 
challenging, especially for critically ill patients in whom, typically, it is important to reliably confirm 
or exclude VTE. Imaging studies for deep vein thrombosis (DVT) or pulmonary embolism (PE) may 
be avoided due to concerns of transmitting infection in non-COVID-19 hospital wards or to healthcare 
workers. The frequent finding of an elevated D-dimer in very ill hospitalized COVID-19 patients may 
prompt an aggressive diagnostic approach for VTE, despite the controversy that a very elevated D-
dimer (>4.0 mg/L) may not be a reliable predictor of VTE in this population but rather a marker of 
poor overall outcome [4,9] . One recent study found a sensitivity of 85.0% and specificity of 88.5% 
for diagnosing VTE in patients with D-dimer levels >1.5 mg/L, but the study was based on a small 
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for lower and upper extremity DVT or bedside echocardiography to assess for right ventricular strain 
associated with PE may be difficult to obtain due to patient instability or the requirement of prone 
positioning in patients with acute respiratory distress syndrome (ARDS), and may lack sufficient 
specificity and sensitivity to diagnose VTE as patients with pneumonia may have right ventricular 
strain without PE [10] . However, in the clinical context of unexplained sudden deterioration of 
pulmonary status or acute lower extremity erythema or swelling, these tests may be useful in aiding 
the clinical suspicion for VTE.
These concerns should be balanced by emerging data that the incidence of VTE in hospitalized 
COVID-19 patients with severe pneumonia or in ICU settings is higher than that reported by 
historical data in similar patients, with an incidence of VTE of 27% (95% confidence interval [CI]: 
17-37) in one study using standard thromboprophylaxis and an incidence of 25% in another study 
without prophylaxis [3,4]. These findings are consistent with high rates of VTE in patients with other 
severe viral pneumonias, such as influenza H1N1, in whom there was an 18- to 23-fold higher risk for 
VTE compared with control patients [5] .
Some clinicians advocate in favor of routine DVT screening in hospitalized COVID-19 
patients using bedside venous ultrasound based on the premise that undiagnosed DVT and resultant 
PE (including microthrombi-related mechanisms) may be an important contributor to hypoxic 
pulmonary vasoconstriction that would lead to pulmonary hypertension and right ventricular failure, 
in addition to worsening of ARDS. Whether routine screening with bedside venous ultrasonography 
or echocardiography to diagnose DVT and PE is useful in managing thromboprophylaxis strategies in 
sick hospitalized COVID-19 patients remains uncertain.
Guidance Statement 1: Diagnosis of VTE in hospitalized COVID-19 patients:
a. Practitioners should use standard-of-care objective testing (i.e., CTPA, V/Q scan, MRI 
venography, Doppler ultrasonography) to diagnose VTE based on clinical index of suspicion. 
A pragmatic approach (i.e., point-of-care bedside ultrasonography or echocardiography) can 
also be combined with standard-of-care objective testing (50% of respondents).
b. Routine screening for VTE using bedside Doppler ultrasonography of the lower extremities or 









This article is protected by copyright. All rights reserved
VTE Prophylaxis in non-ICU Hospitalized COVID-19 Patients
Hospitalized acutely-ill medical patients, including those with infections such as viral 
pneumonia, are at increased risk for VTE, and antithrombotic practice guidelines recommend 
thromboprophylaxis with twice- or thrice-daily subcutaneous unfractionated heparin (UFH) once-
daily subcutaneous low-molecular-weight heparin (LMWH), or fondaparinux to reduce this risk, 
although fondaparinux is infrequently used due to its long half-life and reversibility concerns [11,12]. 
Patients hospitalized with severe COVID-associated pneumonia may have a further heightened risk of 
VTE, but this issue remains unresolved. Preliminary reports in patients with severe pneumonia due to 
COVID-19 as well as previous reports of severe pneumonias/severe acute respiratory syndromes from 
other viruses such as influenza H1N1 or Middle East respiratory syndrome (MERS-CoV) suggest a 
multi-fold higher risk for VTE and, in particular, in increased risk for PE [5] . In addition, patient-
specific VTE risk factors such as advanced age, a prior history of VTE, a history of or active cancer, 
immobility, and thrombophilia, had been incorporated prior to the COVID-19 era to assess overall 
VTE risk using standardized VTE risk assessment scores such as Padua VTE or IMPROVE VTE risk 
scores [8,13,14] , which had been externally validated [15–17]. A recent study from China in 
hospitalized medical patients with COVID-19 reported that 40% of patients had a high risk of VTE 
using the Padua VTE model, although the use of thromboprophylaxis was not reported [18] . The 
optimal VTE risk stratification scheme for hospitalized COVID-19 patients requires further study, 
including the use of very elevated D-dimer levels (>6 times the upper limit of normal [ULN]) that 
appear to be a consistent predictor of thrombotic events and poor overall prognosis in this population 
[19]. However, given the relatively high rates of VTE found in early reports, the use of a “universal” 
thromboprophylactic strategy for all hospitalized patients with COVID-19 appears more appropriate 
than an individualized VTE risk assessment approach at present.
All hospitalized patients with COVID-19 should be considered for thromboprophylaxis with 
either UFH or LMWH unless there are absolute contraindications. Advantages of LMWH over UFH 
include once daily versus twice or thrice daily injections and less heparin-induced thrombocytopenia. 
Although some DOACs are approved for in-hospital prophylaxis, these agents should be considered 
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other experimental therapies may potentiate or interfere with DOAC therapy [7]. Many institutions 
have adopted prophylaxis protocols that use a “stepped up” or intermediate-dose LMWH dose 
regimens based on emerging evidence suggesting increased thrombogenicity with COVID-19, 
especially in sicker patients [20] . For patients in whom anticoagulant therapy is contraindicated, 
mechanical thromboprophylaxis, preferably with intermittent pneumatic compression devices, should 
be utilized, although there is limited evidence of efficacy in hospitalized medically ill patients [11,21]. 
Guidance Statement 2: VTE prophylaxis in non-ICU hospitalized COVID-19 patients:
a) A universal strategy of routine thromboprophylaxis with standard-dose UFH or LMWH 
should be used after careful assessment of bleed risk, with LMWH as the preferred agent. 
Intermediate-dose LMWH may also be considered (30% of respondents).
b) VTE prophylaxis recommendations should be modified based on extremes of body weight, 
severe thrombocytopenia (i.e. platelet counts of 50,000 x 109 per liter or 25,000 x 109 per liter) 
or deteriorating renal function.
VTE Prophylaxis in ICU Hospitalized COVID-19 Patients
Hospitalized COVID-19 patients who are managed in an ICU or CCU setting have an overall 
poor prognosis, with the proportion of severe cases approaching 26% (95% CI: 17.4 -34.9) and 
reported case-fatality rates of 42% [22]. The presence of co-morbid conditions (e.g., cardiovascular 
disease, obesity), a SIC score ≥4, and elevated levels of D-dimer (>6 times ULN), C-reactive protein 
and troponins, and other markers of disseminated intravascular coagulopathy (DIC) as assessed by the 
ISTH scoring system are associated with a worse prognosis [20,23]. It is uncertain whether changes in 
haemostasis parameters are a direct consequence of the SARS-CoV2 virus or a result of a systemic 
inflammatory response syndrome (SIRS) that is produced by a cytokine storm after viral infection 
[24]. In addition, the heightened prothrombotic tendency in the critically ill hospitalized patients with 
COVID-19 pneumonia, leading to VTE and especially, in situ pulmonary artery microthrombi, is 
evident in case series and pathologic studies as an endpoint of pulmonary inflammation [25,26]. One 
study reported an incidence of VTE of 25% (20/81) and a mortality of 40% (8/20) among patients 
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VTE and arterial thromboembolism of 27% and 3.7%, respectively, in 184 COVID-19 patients who 
were in an ICU setting and were receiving standard-dose thromboprophylaxis [3,4]. Lastly, the use of 
tissue plasminogen activator in the treatment of COVID-19-associated ARDS was associated with 
only transient improvement of pulmonary function [27].
The optimal thromboprophylaxis strategy in the critically ill hospitalized COVID-19 patient 
population is uncertain. Emerging clinical data suggests that the use of either prophylactic to 
intermediate doses of LMWH (e.g., enoxaparin, 40-60 mg daily) in very sick COVID-19 patients (D-
dimer >6 times ULN; SIC score ≥4) is associated with improved outcomes and a better prognosis [20] 
. A previous report that assessed treatment-dose UFH in patients with ARDS who were afflicted with 
influenza H1N1, found that patients with H1N1-associated ARDS who received therapeutic 
anticoagulation had 33-fold fewer VTE events than those treated given prophylactic-dose UFH or 
LMWH [5]. Expert clinical guidance statements and clinical pathways from large academic 
healthcare systems favor the use of standard-dose regimens with LMWH or UFH (especially for 
patients with a creatinine clearance < 30 mL/min), mechanical  thromboprophylaxis (intermittent 
pneumatic compression) when anticoagulants were contraindicated, use of multimodal (anticoagulant 
and mechanical) prophylaxis strategies in the critically ill and completely immobile COVID-19 
population [7,28], and the use of VTE risk stratification using either clinical criteria (body mass index 
[BMI] >30 kg/m2), VTE risk scores and/or biomarkers (e.g., very elevated D-dimer levels) to suggest 
intermediate- or higher-dose LMWH or UFH regimens (e.g. enoxaparin 0.5 mg/kg twice-daily; 
enoxaparin 40 mg twice-daily, intravenous UFH targeted to an anti-factor Xa level of 0.30-0.70 
IU/mL). Many institutional protocols of hospitalized COVID-19 patients now incorporate obesity 
(BMI >30kg/m2) or morbid obesity (BMI > 40kg/m2) to administer intermediate-dose LMWH for 
thromboprophylaxis [29].The use of empiric therapeutic-dose anticoagulation has been advocated by 
some for the critically ill hospitalized COVID-19 patients, especially in ICU settings; however, data 
on the efficacy and safety of this approach is limited [3]. There are ongoing randomized trials that aim 
to assess the efficacy and safety of more intense intermediate- to therapeutic-dose versus 
prophylactic-dose LMWH in hospitalized COVID-19 patients including COVID Hep 
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Guidance Statement 3: VTE prophylaxis in sick ICU Hospitalized COVID-19 patients:
a)  Routine thromboprophylaxis with prophylactic-dose UFH or LMWH should be used after 
careful assessment of bleed risk. Intermediate-dose LMWH (50% of respondents) can also be 
considered in high risk patients. Patients with obesity as defined by actual body weight or BMI 
should be considered for a 50% increase in the dose of thromboprophylaxis. Treatment-dose 
heparin should not be considered for primary prevention until the results of randomized 
controlled trials are available.
b) Multi-modal thromboprophylaxis with mechanical methods (i.e., intermittent pneumonic 
compression devices) should be considered (60% of respondents)
Duration of Thromboprophylaxis in Hospitalized COVID-19 Patients
The risk of hospital-associated VTE extends for up to 6 weeks post-hospital discharge in high 
VTE risk medically ill patients, including those with pneumonia, sepsis, and any condition requiring 
management in an ICU setting [30]. At least 60% of all VTE events in medically ill patients occur in 
the post-hospital discharge period, with the first 3 weeks being associated with a greater than 5-fold 
increased risk in fatal PE [14]. Earlier studies of extended thromboprophylaxis with DOACs revealed 
either limited efficacy or an increase in major bleed risk, and particularly due to these safety concerns, 
the most recent antithrombotic guidelines recommended against routine post-discharge 
thromboprophylaxis in medically ill patients, including those with pneumonia [12]. However, more 
recent data reveals that in selected populations at high VTE risk and low bleed risk, based on key risk 
factors or risk models for thrombosis and bleeding, extended-duration thromboprophylaxis for 
approximately 4 weeks with prophylactic-dose LMWH (e.g., enoxaparin, dalteparin, tinzaparin) or a 
DOAC (e.g. rivaroxaban, betrixaban) provides a net clinic benefit by reducing VTE risk without 
incurring a significant increase in the risk of major bleeding [31–33]. This benefit appears more 
pronounced in patients whose index hospitalization was due to infectious disease, particularly 
pneumonia [34]. Recent data also supports that a modified IMPROVE VTE score using established 
cut-offs plus elevated D-dimer (>2 times ULN) identifies patients at an almost three-fold higher risk 
for VTE in whom there is a significant benefit for extended-duration thromboprophylaxis [35]. This 
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the absence of COVID-19-specific data, it is reasonable to consider extended-duration 
thromboprophylaxis with LMWH or a DOAC for at least 2 weeks and up to 6 weeks post-hospital 
discharge in selected COVID-19 patients who are at low risk for bleeding and with key VTE risk 
factors such as advanced age, stay in the ICU, cancer, a prior history of VTE, thrombophilia, severe 
immobility, an elevated D-dimer (>2 times ULN), and an IMPROVE VTE score of 4 or more. 
Guidance Statement 4: Duration of VTE prophylaxis for hospitalized COVID-19 patients:
a) Either LMWH (30%) or a DOAC (i.e., rivaroxaban or betrixaban 30% of respondents) can be 
used for extended-duration thromboprophylaxis.
b) Extended post-discharge thromboprophylaxis should be considered for all hospitalized 
patients with COVID-19 that meet high VTE risk criteria. The duration of post-discharge 
thromboprophylaxis can be approximately 14 days at least (50% of respondents), and up to 30 
days (20% of respondents). 
VTE Treatment in Hospitalized COVID-19 Patients
There are multiple validated and approved strategies to treat hospitalized patients with a new 
VTE including the use of UFH/LMWH bridging therapy to dose-adjusted warfarin, the use of 
UFH/LMWH lead-in therapy with a switch to dabigatran/edoxaban, or a monotherapy approach with 
rivaroxaban/apixaban [36]. In hospitalized COVID-19 patients, parenteral anticoagulation with UFH 
or LMWH may have advantages over other strategies due to the absence of known drug-drug 
interactions with antiviral agents or investigational therapies used to treat COVID-19. Moreover, the 
use of LMWH may have further advantages in this setting due to lack of routine monitoring and 
decrease healthcare worker exposure to infection due to frequent blood draws necessary with IV 
UFH, which may require higher than usual doses from possible heparin resistance due to acute phase 
reactants. DOACs may also have further disadvantages in this setting due to potential drug-drug 
interactions via CYP3A4 mechanisms with certain antivirals (i.e., lopinavir/ritonavir) and 
immunomodulatory investigational COVID-19 therapies, as well as potential for lack of reversal 
agents or specific antidotes in some hospitals [7,28]. However, in the post-hospital discharge setting, 
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for routine monitoring and subsequent minimization of patient contact with the healthcare 
environment.
Guidance Statement 5: VTE treatment in hospitalized COVID-19 patients:
a) Established guidelines should be used to treat patients with confirmed VTE, with 
advantages of LMWH in the inpatient setting and DOACs in the post-hospital 
discharge setting. A change from treatment-dose DOAC or VKA to in-hospital LMWH 
should be considered especially for patients in critical care settings or with relevant 
concomitant medications, and dependent on renal function and platelet counts. 
Anticoagulant regimens should not change based solely on D-dimer levels.
b) A change of anticoagulant regimen (i.e.,from prophylactic or intermediate-dose to 
treatment-dose regimen) can be considered in patients without established VTE but 
deteriorating pulmonary status or ARDS (50% of respondents).
c) The duration of treatment should be at least 3 months (50% of respondents).
Discussion
COVID-19 is emerging as a highly contagious disease with coagulopathic manifestations that 
appear to have unique characteristics. Initial data support a high incidence of thromboembolic disease, 
and especially VTE, in hospitalized COVID-19 patients, as well as poorer outcomes for COVID-19 
patients with pre-existing cardiovascular disease [3,7]. Due to the risk of infectivity with a need to 
minimize contact with healthcare workers and the health system, the diagnosis of VTE in critically ill, 
unstable hospitalized COVID-19 patients (especially in the ICU) that may need prone positioning and 
may not be able to undergo standard objective testing, the potential for new VTE risk stratification 
strategies using novel dosing intensities of established thromboprophylaxis regimens, new paradigms 
of post-hospital discharge and extended thromboprophylaxis, and careful considerations of 
antithrombotic management due to the potential for drug-drug interactions with investigational or 
immunomodulatory therapies, healthcare workers will need to understand special considerations for 
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There is an urgent need for high quality data, especially from randomized controlled trials, 
using a coordinated effort by healthcare funding agencies, organizations dedicated to thrombotic 
disorders, and professional societies, to answer some of the most urgent questions. These urgent 
questions are included in the Table. There is currently one large international registry on VTE 
(RIETE) that is capturing data elements for COVID-19 patients with VTE, and other ongoing 
registries (CORONA-VTE and CORE-19) that are capturing hospital and post-hospital discharge data 
elements for patients with COVID-19. There is also a new registry by the American Heart Association 
planned for cardiovascular outcomes of these patients. Lastly, ongoing and planned randomized trials 
will address key clinical questions, especially the effect of anticoagulation on outcomes in critically ill 
COVID-19 patients and whether more intense thromboprophylaxis strategies improve morbidity and 
mortality in hospitalized COVID-19 patients.
This guidance document, using a consensus-based approach, has attempted to provide useful 
directions for healthcare practitioners managing VTE-related issues in hospitalized COVID-19 
patients. We acknowledge that the lack of an iterative process in our survey produced some guidance 
statements that may not have been supported by a majority of expert panel members. As more data is 
forthcoming, especially high quality data, there needs to be rapid dissemination of this data that 
addresses some of the most urgent clinical issues in this patient population.
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Table. Key Management Issues for VTE in Hospitalized COVID-19 Patients
Topic
Diagnosis of VTE
What is the optimal diagnostic strategy in sick 
hospitalized patients?
Should practitioners use elevated D-dimer to guide 
diagnosis of VTE?
Prophylaxis of VTE
Should practitioners use VTE risk stratification, 
including D-dimer, to determine optimal 
thromboprophylaxis strategy?
Should practitioners use higher than usual (i.e., 
intermediate) doses of UFH/LMWH for VTE 
prophylaxis? Higher than usual dose (i.e. 50% 
increased) in obese patients?
Should practitioners use empiric treatment dose 
UFH/LMWH in the management of sick patients 
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Duration of thromboprophylaxis
What clinical/biomarker criteria and which VTE 
RAM should practitioners use for extended 
thromboprophylaxis?
What is the optimal agent/duration of extended 
thromboprophylaxis?
Treatment of VTE
What is the optimal agent and duration for VTE 



















For hospitalized patients with severe COVID-19, 
how would you advocate the diagnosis of VTE? 
Standard methods using CTPa, V/Q scan, and full 
point extremity Dopplers 
30% 
Pragmatic approach, i.e. bedside POC 2 point LE 
Compression U/S, bedside TTE to assess presence 
of RV strain 
20% 
A combination of both depending upon feasibility 50% 
Does your institution advocate for routine 
screening using LE bedside U/S in severe 
hospitalized COVID patients? 
 20% 
Does your institution utilize elevated D-dimers 
















 Hospitalized patients 
not in the ICU with 
COVID-19 
Hospitalized patients in 
the ICU with severe 
COVID-19 











What type and dose 
of pharmacologic 
thromboprophylaxis 
do you recommend? 
Prophylactic dose LMWH (i.e. 
enoxaparin 40mg SQ QD) 
60% 50% 
Prophylactic dose UFH (i.e. UFH 5000U 
SQ BID or TID) 
20% 30% 
Prophylactic dose fondaparinux (i.e. 
fondaparinux 2.5mg SQ QD) 
0% 0% 
Prophylactic dose DOAC (i.e. 
rivaroxaban 10mg PO QD; apixaban 
2.5mg PO BID, betrixaban 80mg PO 
QD) 
0% 10% 
Intermediate dose LMWH (i.e. 
enoxaparin 40mg SQ BID, 0.5mg/kg SQ 
QD) 
30% 50% 
Intermediate dose UFH (i.e. UFH 
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Intermediate dose fondaparinux (i.e. 
fondaparinux 5.0mg SQ QD) 
0% 10% 
Treatment dose LMWH (i.e. 
enoxaparin 1mg/kg SQ BID) 
10% 10% 
Treatment dose UFH (i.e. UFH IV 
adjusted to aPTT) 
0% 10% 
Treatment dose fondaparinux (i.e. 
fondaparinux 7.5 to 10mg SQ QD) 
0% 0% 
Treatment dose DOAC (i.e. 
rivaroxaban 20mg PO QD; apixaban 
5.0mg PO BID) 
0% 10% 
Multimodal prophylaxis with mechanical methods (i.e. 
IPCs) in addition to pharmacologic measures for 






















For hospitalized patients with severe COVID-














0-14 days 50% 
14-30 days 20% 
> 30 days 0% 









Do you treat hospitalized COVID-19 patients 
with VTE as per your institution's routine 
guidelines? 
90% 
For hospitalized COVID-19 patients with 
suspected VTE, but without a confirmed 
diagnosis of DVT or PE, do you change your 
anticoagulant regimen based on elevated D-
dimer (i.e. > 2 or 3X ULN?) 
20% 
For hospitalized COVID-19 patients with 
deteriorating pneumonitis or ARDS, but 
without a confirmed diagnosis of DVT or PE, 
do you change your anticoagulant regimen? 
 
50% 
What is your 
recommended 
3 months 50% 
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average duration of 
anticoagulation in 
COVID-19 patients 
with established VTE? 























Do you change your VTE 
prophylaxis 
recommendations based on 
extremes of body weight(< 




In obese patients with COVID-
19, at what body weight 
would you increase the dose 
of VTE prophylaxis, typically 
by 50% (e.g., enoxaparin 40 
mg daily to 30 mg twice-
>100 kg (40%) 






















daily)? enoxa 40 mg bid) ) (10%) 
 
BMI>40 (I'd prefer to user the BMI (over 40) 
(10%) 
In thrombocytopenic patients 
with COVID-19, at what 
platelet count would you not 
recommend a weight-
adjusted anticoagulant 
prophylaxis regimen such as 
enoxaparin 40 mg daily or 30 
mg twice-daily (i.e., you 
would recommend 
mechanical prophylaxis 
instead)? 
<25 (50%) 
<30 (10%) 
<50 (30%) 
<100 (10%) 
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